

## Global Biosimilars Market – Products, Applications and Regulations

*“This report reviews, analyzes and projects the global Biosimilars market for the period 2016-2025. Biosimilar product types analyzed in this study comprises Monoclonal Antibodies, Erythropoietin, Granulocyte Colony-Stimulating Factor (G-CSF), Insulin and Other product types (including Interferons, Folitropins, Recombinant Proteins etc.). The report also encompasses the market analysis for Therapeutic Areas consisting Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other therapeutic areas (including Chronic Diseases, Infectious Diseases, Cardiovascular Disorders etc.)”*

Published: May 2019

Report Code: BT010

Pages: 364

Charts: 223

Price: \$4050 Single User License, \$6750 Enterprise License

### Report Synopsis

Cost effectiveness, increasing geriatric population, rising incidences and prevalence of chronic ailments such as Cancer, Autoimmune Disorders and Diabetes and supportive government regulations and guidelines are some of the factors fueling the biosimilars market. Patent expiry of most of the monoclonal antibody based biologics drives the biosimilar monoclonal antibody market. Oncology biosimilar market leads the biosimilars market and is primarily driven by the rising prevalence and incidence of cancer and patent expiry of the expensive biologics. On the other hand, the growth of the biosimilars market is retarded due to insufficient regulatory guidelines, expensive research and development procedures and preference of patented products by the patients, etc.

Monoclonal Antibodies constitute the single largest product type in the global Biosimilars market, demand for which is estimated at US\$4.4 billion in 2018 and is projected to reach US\$28.8 billion by 2025. The overall Biosimilars market in 2019 is expected to reach US\$10.4 billion.

### Research Findings & Coverage

- Global Biosimilars market is analyzed in this report with respect to key product types and major therapeutic areas
- The study exclusively analyzes the market for each product type and therapeutic area of Biosimilars by all major geographic regions/countries globally
- mAbs - All the Rage in Biosimilars' New Wave
- Biosimilars Slashes the Cancer Treatment Cost
- Novel mAb's Purification Approach to Maximize the Biosimilar Production
- Asia: A Preferred Manufacturing Hub for Biosimilars
- Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
- Major companies profiled – 42
- The industry guide includes the contact details for 151 companies

### Product Outline

The report analyzes the market for the following key product types of Biosimilars:

- Monoclonal Antibodies (mAb)
- Erythropoietin (EPO)
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Insulin
- Others (includes Interferons, Folitropins, Recombinant Proteins etc.)

Therapeutic areas of Biosimilars analyzed in this study comprise the following:

- Oncology
- Autoimmune Disorders
- Blood Disorders
- Growth Hormone Deficiency
- Others (includes Chronic Diseases, Infectious Diseases, Cardiovascular Disorders etc.)

### Analysis Period, Units and Growth Rates

- The report reviews, analyzes and projects the global Biosimilars market for the period 2016-2025 in terms of US\$ and the compound annual growth rates (CAGRs) projected from 2018 through 2025

### Geographic Coverage

- **North America** (The United States, Canada and Mexico)
- **Europe** (Germany, the United Kingdom, France, Spain, Italy and Rest of Europe)
- **Asia-Pacific** (China, India, Japan, South Korea and Rest of Asia-Pacific)
- **Rest of World** (Brazil, Israel and Other Rest of World)

Global Biosimilars Market by Product Type 2018-2025



## SAMPLE COMPANY PROFILE

### AXXO GMBH (GERMANY)

Rödingsmarkt 20, 20459 Hamburg, Germany  
 Phone: +49- 40- 389 19 40, Fax: +49- 40- 386 19 409  
 E-Mail: Pharma@AXXO.de  
 Website: www.axxo.de

#### Business Profile

Operating internationally through its 26 operating units and alliances, AXXO GmbH is a renowned leading pharmaceutical healthcare company. The company offers a range of premium standard products and services at affordable prices. The four main divisions of the company comprises of Generics (therapeutic compounds that are similar to the patent expired compounds but at lesser price), Branded products for the health care market, similarity products (copycats of the eminent biologics) and special pharmaceuticals (ex- therapeutic compounds to meet the requirements of the cancer treatment protocol).

#### Product Portfolio

Etanercept: Etanercept is the most recently released biotechnology product. Biosimilar to Enbrel® offered in the concentrations of 25 mg or 50 mg, Etanercept is employed to address Rheumatoid Ailments and Psoriasis.

#### Biotechnology Products

#### Biotechnology Products

Product Name	Indication
<b>Recombinant Human Proteins</b>	
Erythropoietin (EPO)	Post-Cancer Treatment
Interferon alpha 2b	Hepatitis B/C, HIV, Leukemia and Anti-Cancer
Interferon beta 1a / 1b	Multiple Sclerosis
Interleukin 1 ra	Rheumatoid Arthritis
Interleukin 2	Immunotherapy and Anti-Cancer
Filgrastim (G-CSF)	Post-Cancer Treatment
TNF a Fc	Rheumatoid Arthritis
Factor VIII	Blood Clotting Factor for Blood Coagulation
TNF – related apoptosis inducing ligand (TRIAL)	Model of Type 1 Diabetes Treatment
<b>Monoclonal Antibodies</b>	
Rituximab	Rheumatoid Arthritis, Lymphoma and Leukemia
Trastuzumab	Breast Cancer Treatment
Bevacizumab	Metastatic Colon Cancer and non-small Cell Lung Cancer
Infliximab	Autoimmune Disease and Crohn's Disease
Adalimumab	Rheumatoid Arthritis and Psoriatic Arthritis


.....more

## SAMPLE TABLE/CHART

Glance at 2019 Global Biosimilars Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World



European Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million



## KEY PLAYERS PROFILED

- Adello Biologics
- Amgen Inc.
- AXXO GmbH
- BIOCAD
- Biogen, Inc.
- CoherusBioSciences
- Creative BioMart
- Dong-A Socio Group
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly and Company
- Genor Biopharma Co., Ltd.
- Hetero Drugs Limited
- Insud Pharma SL
- Intas Pharmaceuticals Ltd.
- LG Chem
- Lupin Limited
- Mylan, Inc
- Nippon Kayaku Co., Ltd.
- Pfizer, Inc.
- Reliance Life Sciences Pvt. Ltd.
- Sandoz International GmbH
- Shanghai Henlius Biotech, Inc.
- STADA Arzneimittel AG
- Teva Pharmaceutical Industries Limited
- Wockhardt Limited
- Zydus Cadila

.....more

## TABLE OF CONTENTS

<b>PART A: GLOBAL MARKET PERSPECTIVE .....</b>	<b>1</b>		
<b>1. INTRODUCTION .....</b>	<b>1</b>		
1.1 Product Outline.....	4		
1.1.1 Biosimilars Defined .....	4		
1.1.2 Backdrop .....	5		
1.1.3 The Biologics Price Competition and Innovation Act (BPCI Act).....	6		
1.1.3.1 Data Exclusivity .....	6		
1.1.4 Steps Involved in Biosimilar Synthesis .....	7		
1.1.5 Key Regulatory Authorization Pathway – Synopsis .....	7		
1.1.6 Biosimilars Types .....	8		
1.1.6.1 Monoclonal Antibodies (mAb or moAB) .....	8		
1.1.6.1.1 Production Process .....	8		
1.1.6.1.1.1 Hybridoma Cell Production .....	8		
1.1.6.1.2 Therapeutic Applications .....	9		
1.1.6.2 Erythropoietin (EPO) .....	9		
1.1.6.2.1 Functions of EPO .....	10		
1.1.6.2.2 Mechanism of Action .....	10		
1.1.6.2.3 Synthesis and Regulation .....	11		
1.1.6.2.4 Uses in Medicine .....	11		
1.1.6.3 Granulocyte Colony-Stimulating Factor (G-CSF) ..	11		
1.1.6.3.1 Biological Function .....	11		
1.1.6.3.2 Genetics .....	12		
1.1.6.3.3 Use in Therapeutics .....	12		
1.1.6.4 Insulin .....	13		
1.1.6.4.1 Biosimilar Insulin.....	14		
1.1.6.4.2 The Complexity in Producing Biosimilar Insulin .....	15		
1.1.6.4.3 Biosimilar Insulins and the Regulatory Environment Surrounding Them.....	15		
1.1.6.4.4 The Market for Biosimilar Insulins .....	16		
1.1.6.5 Interferons .....	17		
1.1.6.5.1 Interferon Categorization .....	17		
1.1.6.5.2 Functions of Interferons .....	17		
1.1.6.5.3 Interferon Alfa .....	18		
1.1.6.5.4 Interferon Beta-1a .....	18		
1.1.6.5.5 Interferon Gamma .....	19		
1.1.6.6 Human Growth Hormone .....	20		
1.1.6.6.1 Recombinant Human Growth Hormone ..	20		
1.1.6.6.2 Managing Growth Disorders Using Recombinant Human Growth Hormone Biosimilars ..	21		
1.1.6.7 Other Biosimilars .....	21		
1.1.7 Biosimilars Therapeutic Areas.....	22		
1.1.7.1 Oncology .....	22		
1.1.7.1.1 Biosimilar G-CSF .....	24		
1.1.7.2 Autoimmune Diseases .....	25		
1.1.7.3 Blood Disorders.....	27		
1.1.7.4 Growth Hormone Deficiency (GHD).....	28		
1.1.7.4.1 Growth Hormone Deficiency in Children ..	29		
1.1.7.5 Infectious Diseases .....	29		
1.1.7.5.1 Treatment of Infectious Diseases.....	30		
<b>2. REGULATORY LANDSCAPE.....</b>	<b>31</b>		
2.1 The United States Food and Drug Administration (USFDA) .....	31		
2.1.1 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product .....	31		
2.1.2 Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product .....	32		
2.1.3 Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 .....	32		
2.2 European Medicines Agency (EMA) .....	32		
2.3 The World Health Organization (WHO).....	33		
2.4 Canada .....	34		
2.5 South Korea .....	35		
2.6 China .....	35		
2.7 India .....	36		
2.8 Japan .....	38		
2.9 Mexico .....	39		
2.10 Brazil .....	39		
2.11 Argentina .....	39		
<b>3. KEY MARKET TRENDS.....</b>	<b>40</b>		
3.1 mAbs - All The Rage In Biosimilars' New Wave ..	40		
3.1.1 The Buildup to the Biosimilar Industry.....	40		
3.1.2 Current Players: A Sneak Preview .....	42		
3.2 Biosimilars Slashes the Cancer Treatment Cost ..	43		
3.3 Emerging Markets to Drive Biosimilars Growth ..	43		
3.4 Asia: A Preferred Manufacturing Hub for Biosimilars .....	44		
3.5 SPC Manufacturing Waiver Initiated by EU Commission .....	46		
3.6 Novel mAb's Purification Approach to Maximize the Biosimilar Production .....	46		
3.7 Biosimilars and "Patent Dance" .....	47		
<b>4. RECENT BIOSIMILARS APPROVALS .....</b>	<b>48</b>		
<b>5. KEY GLOBAL PLAYERS.....</b>	<b>52</b>		
Adello Biologics (United States) .....	52		
Amgen Inc. (United States) .....	53		
AXXO GmbH (Germany) .....	54		
BIOCAD (Russia) .....	55		
Biogen, Inc. (United States).....	56		
CoherusBioSciences (United States).....	57		
Creative BioMart (United States) .....	58		
Dong-A Socio Group (South Korea) .....	59		
Dr. Reddy's Laboratories Ltd. (India) .....	60		
Eli Lilly and Company (United States) .....	61		
Genor Biopharma Co., Ltd. (China).....	62		
Hetero Drugs Limited (India) .....	63		
Insud Pharma SL (Spain) .....	64		
mAbxience SA (Spain) .....	64		
Intas Pharmaceuticals Ltd. (India) .....	65		
LG Chem (South Korea) .....	66		
Lupin Limited (India) .....	67		
Mylan, Inc (United States) .....	68		
Nippon Kayaku Co., Ltd. (Japan) .....	69		
Pfizer, Inc. (United States).....	70		
Reliance Life Sciences Pvt. Ltd. (India).....	71		
Sandoz International GmbH (Germany) .....	72		
Shanghai Henlius Biotech, Inc. (China) .....	73		
STADA Arzneimittel AG (Germany) .....	75		
Teva Pharmaceutical Industries Limited (Israel) .....	76		
Wockhardt Limited (India) .....	77		
Zydus Cadila (India) .....	78		
<b>6. KEY BUSINESS AND PRODUCT TRENDS .....</b>	<b>79</b>		
Samsung Bioepis Signs Biosimilars Development and Marketing Agreement with C-Bridge Capital.....	79		
Biosimilar Association of Samsung Bioepis and 3SBio.....	79		
Kashiv Pharma Renamed as KashivBioSciences After Acquiring Adello Biologics .....	79		
Japanese Release of Trastuzumab and Agalsidase Beta Biosimilar .....	80		
Epoetin Alfa and Pegfilgrastim Biosimilars Now Accessible In the US at Considerable Concession .....	80		
Biosimilars of Insulin Glargine Introduced in South Korea and the UK .....	80		
CNDA Accepted Review of Adalimumab Biosimilar .....	81		
Filgrastim Biosimilar Application Submitted to the US FDA ..	81		
European Commercial Release of Amgevita and Imraldi ..	81		
MHLW of Japan Received Approval Application for Dual Darbepoetin Alfa Copy Biologics .....	81		
Evaluation of Adalimumab Biosimilar SB5 by USFDA .....	82		
Acceptance of Approval Application by CFDA for Adalimumab Biosimilar .....	82		
Review Acceptance for Mabion CD20 by EMA and Rituxan Expanded the Therapeutic Range .....	82		
Dr Reddy's Introduces Hervycta, A Trastuzumab Biosimilar in India.....	83		
Resubmission of Marketing Approval of Biosimilar Rituximab to FDA by Celltrion.....	83		
Refusal of Trastuzumab and Rituximab Biosimilars Approval Applications by FDA.....	83		
Rejection of Rituximab and Trastuzumab of Celltrion/Teva by FDA .....	83		
Ontruzant Trastuzumab Biosimilar Released in the UK... ..	84		
Commercialization of Trastuzumab Biosimilar in South Korea By Daewoong .....	84		
Commercial Release of Adalimumab Biosimilar in India by Hetero .....	84		
Production of Denosumab Biosimilar in Australia.....	85		
Acceptance of Applications for Adalimumab and Trastuzumab by FDA .....	85		
USV's Filing for Pegfilgrastim Accepted by EMA .....	85		
Acceptance of Pegfilgrastim and Trastuzumab Fillings by EMA.....	85		
Introduction of Kraveva, a Bevacizumab Biosimilar, in India .....	86		
Pegfilgrastim Filling Acceptance by EMA .....	86		
Danish Company Appeals FDA for Clinical Studies Data of Victoza Copy Biologics .....	86		
Postponement of Pegfilgrastim Biosimilar Approval of Biocon/Mylan by FDA .....	86		
Acceptance of Pegfilgrastim Biosimilar Filling of Cinfa by EMA.....	87		
The US Commercial Release of Adalimumab Biosimilar of Amgen After January 2023 .....	87		
Submission of Approval Application by JCR for Agalsidase Beta Biosimilar in Japan.....	87		
Acceptance of Approval Filing of Filgrastim Biosimilar of Adello by FDA .....	88		
Application Acceptance of Sandoz's Rituximab Biosimilar by FDA .....	88		
Successful Submission of Dual Trastuzumab Biosimilar to the US FDA for Review .....	88		
Biosimilar Business of Merck Taken Over by Fresenius Kabi ..	88		
Merck Introduces RENFLEXIS in the US Market .....	89		
Initiation of Phase III Interchangeability Study of Adalimumab Biosimilar by Boehringer .....	89		
Acceptance of Regulatory Submission for Rituximab Biosimilar of Celltrion/Teva by FDA .....	89		
Refusal of Approval Application of Epoetin Alfa Biosimilar of Pfizer by FDA .....	90		
Registration of Biocad's Rituximab Biosimilars in Honduras and Bolivia.....	90		
Re-evaluation of Bevacizumab and Trastuzumab by FDA Advisory Board .....	90		
Rejection of Pegfilgrastim Biosimilar of Coherus by FDA ..	91		
EMA Acceptance of Sandoz's Adalimumab and Infiximab Biosimilars for Re-evaluation.....	91		
Epoetin Alfa of Pfizer Receives Approval Recommendation from FDA Advisors.....	91		
Approval Application Acceptance of Fujifilm's Adalimumab Biosimilar by EMA.....	92		
Australian Commercial Release of Infiximab Biosimilar in Second half of 2017 .....	92		
Submission of Approval Application in Japan for Trastuzumab Biosimilar .....	92		
Introduction of Basal Analogue Insulin Biosimilar in Indonesia .....	92		
Acceptance of Pegfilgrastim Filling of Mylan/Biocon by FDA ..	93		
Japanese Approval Application Filed for Etanercept Biosimilar.....	93		
Filing of Biosimilar Adalimumab Application by Boehringer to FDA and EMA As Well.....	93		
Withdrawal of Biosimilar Pegfilgrastim Application by Sandoz .....	93		
<b>7. GLOBAL MARKET OVERVIEW .....</b>	<b>94</b>		
7.1 Global Biosimilars Market Overview by Product Type.....	95		
7.1.1 Global Biosimilars Product Types Market Overview by Geographic Region.....	97		



7.1.1.1 Monoclonal Antibodies.....	97	8.5.5 Italy .....	175	10.2.1.3 G-CSF .....	246
7.1.1.2 Erythropoietin.....	99	8.5.5.1 Italian Biosimilars Market Overview by Product Type .....	176	10.2.1.4 Insulin .....	248
7.1.1.3 G-CSF .....	101	8.5.5.2 Italian Biosimilars Market Overview by Therapeutic Area .....	178	10.2.1.5 Other Product Types.....	250
7.1.1.4 Insulin .....	103	<b>8.5.6 Rest of Europe.....</b>	<b>180</b>	10.3 Asia-Pacific Biosimilars Market Overview by Therapeutic Area .....	252
7.1.1.5 Other Product Types.....	105	8.5.6.1 Rest of Europe Biosimilars Market Overview by Product Type.....	181	10.3.1 Asia-Pacific Biosimilars Therapeutic Area Market Overview by Geographic Region .....	254
7.2 Global Biosimilars Market Overview by Therapeutic Area .....	107	8.5.6.2 Rest of Europe Biosimilars Market Overview by Therapeutic Area .....	183	10.3.1.1 Oncology .....	254
7.2.1 Global Biosimilars Therapeutic Area Market Overview by Geographic Region.....	109	<b>9. NORTH AMERICA .....</b>	<b>185</b>	10.3.1.2 Autoimmune Disorders.....	256
7.2.1.1 Oncology.....	109	9.1 North American Biosimilars Market Overview by Geographic Region .....	186	10.3.1.3 Blood Disorders .....	258
7.2.1.2 Autoimmune Disorders.....	111	9.2 North American Biosimilars Market Overview by Product Type .....	188	10.3.1.4 Growth Hormone Deficiency .....	260
7.2.1.3 Blood Disorders.....	113	9.2.1 North American Biosimilars Product Types Market Overview by Geographic Region .....	190	10.3.1.5 Other Therapeutic Areas.....	262
7.2.1.4 Growth Hormone Deficiency .....	115	9.2.1.1 Monoclonal Antibodies.....	190	10.4 Major Market Players .....	264
7.2.1.5 Other Therapeutic Areas.....	117	9.2.1.2 Erythropoietin.....	192	3S BIO, Inc (China) .....	264
<b>PART B: REGIONAL MARKET PERSPECTIVE..119</b>		9.2.1.3 G-CSF .....	194	Biocon Limited (India).....	265
<b>REGIONAL MARKET OVERVIEW.....</b>	<b>121</b>	9.2.1.4 Insulin .....	196	Biogenomics Limited (India) .....	266
<b>8. EUROPE .....</b>	<b>121</b>	9.2.1.5 Other Product Types.....	198	Bioviz Technologies Pvt. Ltd. (India) .....	267
8.1 European Biosimilars Market Overview by Geographic Region.....	122	9.3 North American Biosimilars Market Overview by Therapeutic Area .....	200	Celltrion, Inc. (South Korea).....	268
8.2 European Biosimilars Market Overview by Product Type.....	124	9.3.1 North American Biosimilars Therapeutic Area Market Overview by Geographic Region .....	202	Dong-A Socio Group (South Korea).....	269
8.2.1 European Biosimilars Product Types Market Overview by Geographic Region.....	126	9.3.1.1 Oncology.....	202	Dr. Reddy's Laboratories Ltd. (India).....	270
8.2.1.1 Monoclonal Antibodies.....	126	9.3.1.2 Autoimmune Disorders.....	204	Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan) .....	271
8.2.1.2 Erythropoietin.....	128	9.3.1.3 Blood Disorders .....	206	Genor Biopharma Co., Ltd. (China) .....	272
8.2.1.3 G-CSF .....	130	9.3.1.4 Growth Hormone Deficiency .....	208	Hetero Drugs Limited (India) .....	273
8.2.1.4 Insulin .....	132	9.3.1.5 Other Therapeutic Areas.....	210	Intas Pharmaceuticals Ltd (India).....	274
8.2.1.5 Other Product Types.....	134	9.4 Major Market Players .....	212	LG Chem (South Korea) .....	275
8.3 European Biosimilars Market Overview by Therapeutic Area .....	136	Adello Biologics (United States).....	212	Lupin Limited (India).....	276
8.3.1 European Biosimilars Therapeutic Area Market Overview by Geographic Region.....	138	Amgen Inc. (United States).....	213	Nippon Kayaku Co., Ltd. (Japan) .....	277
8.3.1.1 Oncology.....	138	Biogen, Inc. (United States).....	214	Reliance Life Sciences Pvt. Ltd. (India) .....	278
8.3.1.2 Autoimmune Disorders.....	140	CoherusBioSciences(United States) .....	214	Samsung Bioepis Co., Ltd. (South Korea) .....	279
8.3.1.3 Blood Disorders.....	142	Creative BioMart(United States) .....	215	SciGen Pte. Ltd. (Singapore) .....	280
8.3.1.4 Growth Hormone Deficiency .....	144	Eli Lilly and Company (United States).....	216	Shanghai Henlius Biotech, Inc. (China).....	281
8.3.1.5 Other Therapeutic Areas.....	146	Harvest Moon Pharmaceuticals USA, Inc. (US).....	217	Siam Bioscience Co., Ltd. (Thailand) .....	283
8.4 Major Market Players .....	148	Momenta Pharmaceuticals Inc. (United States).....	219	Wockhardt Limited (India).....	284
Alvotech (Iceland).....	148	Mylan, Inc (United States).....	220	YL Biologics Limited (Japan) .....	285
AXXO GmbH (Germany).....	149	Pfizer, Inc. (United States).....	221	Zydus Cadila (India) .....	286
BIOCAD (Russia).....	150	9.5 Country-wise Analysis of North American Biosimilars Market.....	222	10.5 Country-wise Analysis of Asia-Pacific Biosimilars Market .....	287
Insud Pharma SL (Spain).....	151	<b>9.5.1 The United States.....</b>	<b>222</b>	<b>10.5.1 China.....</b>	<b>287</b>
mAbxience SA (Spain).....	151	9.5.1.1 United States Biosimilars Market Overview by Product Type .....	223	10.5.1.1 Chinese Biosimilars Market Overview by Product Type .....	288
Sandoz International GmbH (Germany).....	152	9.5.1.2 United States Biosimilars Market Overview by Therapeutic Area .....	225	10.5.1.2 Chinese Biosimilars Market Overview by Therapeutic Area .....	290
STADA Arzneimittel AG (Germany).....	153	<b>9.5.2 Canada.....</b>	<b>227</b>	<b>10.5.2 India.....</b>	<b>292</b>
UGA Biopharma GmbH (Germany) .....	154	9.5.2.1 Canadian Biosimilars Market Overview by Product Type .....	228	10.5.2.1 Indian Biosimilars Market Overview by Product Type .....	293
8.5 Country-wise analysis of European Biosimilars Market .....	155	9.5.2.2 Canadian Biosimilars Market Overview by Therapeutic Area .....	230	10.5.2.2 Indian Biosimilars Market Overview by Therapeutic Area .....	295
<b>8.5.1 Germany.....</b>	<b>155</b>	<b>9.5.3 Mexico.....</b>	<b>232</b>	<b>10.5.3 Japan .....</b>	<b>297</b>
8.5.1.1 German Biosimilars Market Overview by Product Type .....	156	9.5.3.1 Mexican Biosimilars Market Overview by Product Type .....	233	10.5.3.1 Japanese Biosimilars Market Overview by Product Type .....	298
8.5.1.2 German Biosimilars Market Overview by Therapeutic Area .....	158	9.5.3.2 Mexican Biosimilars Market Overview by Therapeutic Area .....	235	10.5.3.2 Japanese Biosimilars Market Overview by Therapeutic Area .....	300
<b>8.5.2 United Kingdom.....</b>	<b>160</b>	<b>10. ASIA-PACIFIC.....</b>	<b>237</b>	<b>10.5.4 South Korea .....</b>	<b>302</b>
8.5.2.1 United Kingdom Biosimilars Market Overview by Product Type.....	161	10.1 Asia-Pacific Biosimilars Market Overview by Geographic Region .....	238	10.5.4.1 South Korean Biosimilars Market Overview by Product Type.....	303
8.5.2.2 United Kingdom Biosimilars Market Overview by Therapeutic Area .....	163	10.2 Asia-Pacific Biosimilars Market Overview by Product Type .....	240	10.5.4.2 South Korean Biosimilars Market Overview by Therapeutic Area .....	305
<b>8.5.3 France.....</b>	<b>165</b>	10.2.1 Asia-Pacific Biosimilars Product Types Market Overview by Geographic Region.....	242	<b>10.5.5 Rest of Asia-Pacific .....</b>	<b>307</b>
8.5.3.1 French Biosimilars Market Overview by Product Type .....	166	10.2.1.1 Monoclonal Antibodies.....	242	10.5.5.1 Rest of Asia-Pacific Biosimilars Market Overview by Product Type.....	308
8.5.3.2 French Biosimilars Market Overview by Therapeutic Area .....	168	10.2.1.2 Erythropoietin.....	244	10.5.5.12 Rest of Asia-Pacific Biosimilars Market Overview by Therapeutic Area .....	310
<b>8.5.4 Spain .....</b>	<b>170</b>	<b>11. REST OF WORLD .....</b>	<b>312</b>	<b>11.1 Rest of World Biosimilars Market Overview by Geographic Region .....</b>	<b>313</b>
8.5.4.1 Spanish Biosimilars Market Overview by Product Type .....	171	11.1 Rest of World Biosimilars Market Overview by Product Type .....	315	11.2 Rest of World Biosimilars Market Overview by Product Type .....	317
8.5.4.2 Spanish Biosimilars Market Overview by Therapeutic Area .....	173	11.2.1 Rest of World Biosimilars Product Types Market Overview by Geographic Region .....	317	11.2.1.1 Monoclonal Antibodies.....	317

11.2.1.2 Erythropoietin.....	319	11.5 Country-wise Analysis of Rest of World Biosimilars Market.....	341	11.5.3.2 Other Countries Biosimilars Market Overview by Therapeutic Area .....	354
11.2.1.3 G-CSF .....	321	<b>11.5.1 Brazil.....</b>	<b>341</b>	<b>PART C: GUIDE TO THE INDUSTRY.....</b>	<b>356</b>
11.2.1.4 Insulin .....	323	11.5.1.1 Brazilian Biosimilars Market Overview by Product Type .....	342	1. NORTH AMERICA .....	356
11.2.1.5 Other Product Types.....	325	11.5.1.2 Brazilian Biosimilars Market Overview by Therapeutic Area .....	344	2. EUROPE.....	357
11.3 Rest of World Biosimilars Market Overview by Therapeutic Area .....	327	<b>11.5.2 Israel.....</b>	<b>346</b>	3. ASIA-PACIFIC.....	359
11.3.1 Rest of World Biosimilars Therapeutic Area Market Overview by Geographic Region .....	329	11.5.2.1 Israeli Biosimilars Market Overview by Product Type .....	347	4. REST OF WORLD .....	362
11.3.1.1 Oncology.....	329	11.5.2.2 Israeli Biosimilars Market Overview by Therapeutic Area .....	349	<b>PART D: ANNEXURE.....</b>	<b>363</b>
11.3.1.2 Autoimmune Disorders.....	331	<b>11.5.3 Other Countries.....</b>	<b>351</b>	1. RESEARCH METHODOLOGY .....	363
11.3.1.3 Blood Disorders .....	333	11.5.3.1 Other Countries Biosimilars Market Overview by Product Type.....	352	2. FEEDBACK .....	365
11.3.1.4 Growth Hormone Deficiency .....	335				
11.3.1.5 Other Therapeutic Areas.....	337				
11.4 Major Market Players .....	339				
AMEGA Biotech (Argentina) .....	339				
Teva Pharmaceutical Industries Limited (Israel) .....	340				

## About Industry Experts

Industry Experts’ market research, backed by years of experience and an analytical team dedicated to providing the most optimal business solutions, has been specifically designed to provide a variety of benefits, both current and future. Our leading-edge publications make the life easy for corporate strategists, investors, analysts and researchers, startups, consultants, financial and banking executives, academicians and many more. The company also provides customized research reports to cater the needs of the industry.

Business intelligence provides the critical link between comprehending prevailing market conditions and devising strategies to maximize parameters, such as revenues, profits and return on investment in order to gain market share. The significance of market research can be largely understood through the range of factors that impact businesses. These can comprise market size (current and projected), geographic market reach and demand and supply scenario, to name a few. Our ongoing quest to collect up to date and accurate information by conducting online surveys, personal interviews, taking the opinions of senior level executives will enable us to serve our clients better in every possible aspect.

[More about Industry Experts](#)



**Industry Experts, Inc.**  
 14726 Ramona Ave, Suite S2  
 Chino, CA 91710  
 Greater Los Angeles  
 United States  
 Phone: +1-320-iXPERTS (497-3787)

**India Office**  
 1-7-19/C, Street No. 8, Habsiguda  
 Hyderabad – 500007  
 India  
 Phone: +91-40-4018-1314  
 Fax: +91-40-2715-7746

Email: [info@industry-experts.com](mailto:info@industry-experts.com)

Website: <http://industry-experts.com>